Guess who's more at risk for recurrent wet macular degeneration?

A retrospective cohort study which reviewed 343 Asian eyes with subfoveal neovascular AMD, which was treated with three monthly anti-VEGF injections of ranibizumab found a link between age and gender and the likelihood of recurrence of the condition. Older men were the patients who required re-treatement within twelve months of their initial treatment. At the two-year follow-up mark, 74.8% of the eyes treated experienced a recurrence. Those patients with polypoidal choroidal vasculopathy form of AMD had a notably shorter interval of recurrence than those patients with the typical form of AMD. This study data may help researchers in predicting the risk of recurrence and thus allow doctors to be able to determine the most appropriate follow-up treatment strategy for AMD patients.